LENZ Therapeutics shares are trading higher after Raymond James initiated coverage on the stock with a Buy rating and announced a price target of $37.
Portfolio Pulse from Benzinga Newsdesk
LENZ Therapeutics shares rose following Raymond James' initiation of coverage with a Buy rating and a $37 price target.
September 27, 2024 | 5:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
LENZ Therapeutics shares increased after Raymond James initiated coverage with a Buy rating and set a price target of $37, indicating positive analyst sentiment.
The initiation of coverage by Raymond James with a Buy rating and a specific price target of $37 is a strong positive signal for investors, likely leading to increased buying interest and a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100